Mean Platelet Volume Determines Crimean-Congo Hemorrhagic Fever Prognosis
|
By LabMedica International staff writers Posted on 28 Sep 2015 |
|
Image: The ABBOTT CELL DYN RUBY Hematology Analyzer (Photo courtesy of Abbot Diagnostics).
Crimean-Congo hemorrhagic fever virus (CCHF), a Nairovirus within the family Bunyaviridae, causes severe disease and pancytopenia, organ failures and disseminated intravascular coagulation may occur as a result of CCHF infection.
Changes in the mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in patients that have recovered from non-fatal CCHF can be predictors for the duration of hospitalization and prognosis.
Scientists at the Recep Tayyip Erdogan University (Rize, Turkey) studied a total of 50 CCHF patients including 27 males and 23 females and a similar age group of 47 healthy individuals including 27 males and 20 females) were included in the study. Hematologic and biochemical tests inclusive of C-reactive protein were conducted on patients and controls. Blood samples were checked for CCHF nucleic acids by real-time reverse transcriptase polymerase chain reaction (RT-PCR).
Biochemical tests were performed using photometric assays using the Abbott Architect c16000 analyzer (Abbott Diagnostics; Abbott Park, IL, USA). Hematological tests for hemoglobin, platelets, white blood cell counts (WBC), and MPV were performed using the Abbott Cell-Dyn Ruby analyzer. The C-reactive protein (CRP) test was performed using the nephelometric method in the Coulter Image 800 autoanalyzer (Beckman Coulter; Fullerton, CA, USA).
The MPV was statistically higher at 8.4 fL (range 6.4 to 9.4 fL) in patients than that of controls at 7.0 fL (range 6.0 to 8.7 fL). The NLR and PLR were similar in both groups. The predictors of the length of hospitalization included decreased white blood (WBC) cell and platelet counts, together with elevated prothrombin time (PT), creatinine and glucose levels. Bicytopenia and pancytopenia could also be seen in patients with CCHF. In severe cases, neutropenia and severe thrombocytopenia are also frequently encountered.
The authors concluded that the MPV was higher in patients, but NLR and PLR were similar in both groups. The MPV, NLR and PLR did not serve as predictors of hospitalization length. However, elevation of PT, creatinine, glucose, along with decreased WBC and platelets counts were found to be predictors of hospitalization period. The study was published in the September 2015 issue of Journal of Microbiology and Infectious Diseases.
Related Links:
Recep Tayyip Erdogan University
Abbott Diagnostics
Beckman Coulter
 Analyzer.jpg)
Changes in the mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in patients that have recovered from non-fatal CCHF can be predictors for the duration of hospitalization and prognosis.
Scientists at the Recep Tayyip Erdogan University (Rize, Turkey) studied a total of 50 CCHF patients including 27 males and 23 females and a similar age group of 47 healthy individuals including 27 males and 20 females) were included in the study. Hematologic and biochemical tests inclusive of C-reactive protein were conducted on patients and controls. Blood samples were checked for CCHF nucleic acids by real-time reverse transcriptase polymerase chain reaction (RT-PCR).
Biochemical tests were performed using photometric assays using the Abbott Architect c16000 analyzer (Abbott Diagnostics; Abbott Park, IL, USA). Hematological tests for hemoglobin, platelets, white blood cell counts (WBC), and MPV were performed using the Abbott Cell-Dyn Ruby analyzer. The C-reactive protein (CRP) test was performed using the nephelometric method in the Coulter Image 800 autoanalyzer (Beckman Coulter; Fullerton, CA, USA).
The MPV was statistically higher at 8.4 fL (range 6.4 to 9.4 fL) in patients than that of controls at 7.0 fL (range 6.0 to 8.7 fL). The NLR and PLR were similar in both groups. The predictors of the length of hospitalization included decreased white blood (WBC) cell and platelet counts, together with elevated prothrombin time (PT), creatinine and glucose levels. Bicytopenia and pancytopenia could also be seen in patients with CCHF. In severe cases, neutropenia and severe thrombocytopenia are also frequently encountered.
The authors concluded that the MPV was higher in patients, but NLR and PLR were similar in both groups. The MPV, NLR and PLR did not serve as predictors of hospitalization length. However, elevation of PT, creatinine, glucose, along with decreased WBC and platelets counts were found to be predictors of hospitalization period. The study was published in the September 2015 issue of Journal of Microbiology and Infectious Diseases.
Related Links:
Recep Tayyip Erdogan University
Abbott Diagnostics
Beckman Coulter
Gold Member
Hematology Analyzer
Medonic M32B
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Laboratory Software
ArtelWare
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more